Bitterman Robert J's Form 4 filing
Phio Pharmaceuticals Corp. (PHIO) · filed Jul 5, 2023
- Accession no.
- 0001209191-23-041254
- Filed
- Jul 5, 2023
- Trade date
- Jun 30-Jul 1, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $5.72K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bitterman Robert JCIK 0001304395 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2023 | Common stock, $0.0001 par value | PPurchaseAcquired | +1,000 | $2.88 | +$2,880 | 18,211 | Direct | |
| Jul 1, 2023 | Common stock, $0.0001 par value | PPurchaseAcquired | +1,000 | $2.84 | +$2,840 | 19,211 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.